<DOC>
	<DOC>NCT01097681</DOC>
	<brief_summary>The primary objective of this study is to compare the pharmacokinetics of ASP1941 in type 2 diabetes mellitus patients with normal renal function and those with mild or moderate renal impairment.</brief_summary>
	<brief_title>A Study to Assess the Pharmacokinetics, Pharmacodynamics of ASP1941 in Diabetes Mellitus Patients With Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Type 2 diabetic patients for at least 12 weeks Fasting plasma glucose level of &lt; 240 mg/dL Body Mass Index ( BMI )20.0 35.0kg/m2 GFR value based on the Japanese GFR estimation equation at screening, of â‰¥ 30 ml/min/1.73m2 Type 1 diabetes mellitus patients Receiving insulin within 12 weeks before screening Diabetic ketoacidosis Dysuria and/or urinary tract infection, genital infection Significant renal, hepatic or cardiovascular diseases Severe gastrointestinal diseases</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>ASP1941</keyword>
	<keyword>Diabetes mellitus</keyword>
	<keyword>Urinary glucose excretion</keyword>
</DOC>